Angioimmunoblastic T cell lymphoma in an ankylosing spondylitis patient treated with etanercept

REFERENCES

• Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol. 2003;121:681–91.
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837–43.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol. 2007;14:348–53.
   Google Scholar
• Layton MA, Musgrove C, Dawes PT. Polyarthritis, rash and lymphadenopathy: case reports of two patients with angioimm-unoblastic lymphadenopathy presenting to a rheumatology clinic. Clin Rheumatol. 1998;17:148–51.
   Google Scholar
• Xu L. Ankylosing spondylitis combined with angioimmunob-lastic T cell lymphoma. BMJ Case Reports. 2011.
   Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.
   PubMed Web of Science ®Google Scholar
• Tsochatzis E, Vassilopoulos D, Deutsch M, Filiotou A, Tasidou A, Archimandritis AJ. Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. J Clin Rheumatol. 2005;11:326–8.
   PubMed Web of Science ®Google Scholar
• Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthrop-athy: clinical and biological comparison with early onset patients. Ann Rheum Dis. 1997;56:176–9.
   Google Scholar
• Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prey. 2006;15:2069–77.
   Google Scholar
• Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Myllykangas-Luosujärvi R, Kaipiainen-Seppänen 0, Nousiainen T. Autologous stem cell transplantation in a lym-phoma patient with a long history of ankylosing spondylitis. Rheumatology. 2000;39:563–4.
   Google Scholar
• Khan SY, Hutchinson DG. Primary synovial non-Hodgkin's lymphoma in association with ankylosing spondylitis. Rheuma-tology. 2004;43:391.
   PubMed Web of Science ®Google Scholar
• Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis. 2006;65:1184–7.
   PubMedGoogle Scholar
• Aksu K, Donmez A, Ertan Y, Keser G, Inal V, Oder G, et al. Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int. 2007;28:185–7.
   PubMed Web of Science ®Google Scholar
• Aksu K, Cagirgan S, Ozsan N, Keser G, Sahin F. Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int. 2011;31:1645–7.
   Google Scholar
• Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vol-lenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.
   PubMed Web of Science ®Google Scholar
• Askling J, Baecklund E. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648–53.
   PubMed Web of Science ®Google Scholar
• Nannini C, Cantini F, Niccoli L, Cassarà E, Salvarani C, Ofivieri I, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum. 2009;61: 801–12.
   Google Scholar
• Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum. 2012;64:21–32.
   Google Scholar
• Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008;58:2257–67.
   Google Scholar
• Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol. 2010;30:45–52.
   PubMed Web of Science ®Google Scholar
• Callan MF. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol. 2004;16: 399–405.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein—Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57: 762–7.
   PubMed Web of Science ®Google Scholar
• Couderc M, Payet S, Henquell C, Dubost JJ, Soubrier M. TNFa antagonist therapy does not increase the Epstein—Barr virus burden in patients with rheumatoid arthritis or ankylosing spon-dylitis. Joint Bone Spine. 2010;77:414–7.
   Google Scholar
• Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma devel-opment: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151–8.
   Google Scholar